Table 2.
Demographic data and baseline characteristics of study participants
| Normal values | Treatment group (17) | Control group (14) | P value | |
|---|---|---|---|---|
| Age (yr) | 63.8 ± 8.1 | 64.2 ± 7.3 | 0.870 | |
| BMI (kg/m2) | 25.2 ± 4.5 | 26.7 ± 3.1 | 0.290 | |
| Age at menopause (yr) | 48.8 ± 4.6 | 46.6 ± 4.7 | 0.196 | |
| Lumbar BMD (g/cm2) | 0.67 ± 0.16 | 0.71 ± 0.06 | 0.370 | |
| Femoral BMD | 0.59 ± 0.07 | 0.60 ± 0.06 | 0.709 | |
| Lumbar T-score | −3.11 ± 0.43 | −3.01 ± 0.62 | 0.615 | |
| Femoral T-score | −2.32 ± 0.63 | −2.29 ± 0.46 | 0.832 | |
| Homocysteine (μmol/L) | 5-20 | 11.70 ± 6.63 | 14.07 ± 3.60 | 0.242 |
| Vit B12 (Pg/ml) | 160-970 | 745.70 ± 623.07 | 435.75 ± 245.25 | 0.091 |
| OC (ng/ml) | 12.8-55.0 | 15.34 ± 6.94 | 15.66 ± 9.99 | 0.916 |
| BALP (U/L) | 14.2-42.7 | 29.94 ± 11.02 | 31.17 ± 11.90 | 0.767 |
| UPYD (μg/mmol cr) | 16.0-37.0 | 42.99 ± 11.67 | 43.61 ± 11.14 | 0.882 |
| U β cross laps (μg/mmol cr) | 0.73-7.07 | 2.45 ± 1.58 | 3.10 ± 1.75 | 0.285 |
All data are presented as Mean ± SD. Yr = year; BMI = body mass index; BMD = bone mineral density; Vit B12 = vitamin B12; OC = osteocalcin; BALP = bone alkaline phosphatase; UPYD = urine pyridinium cross links; U β cross laps = urine β cross laps.